Your session is about to expire
← Back to Search
Vitamin K
Vitamin K to Slow Progression of Cardiovascular Disease Risk in Hemodialysis Patients
N/A
Waitlist Available
Led By Norman K Pollock, PhD
Research Sponsored by Augusta University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change from baseline to 8 weeks
Summary
This trial is testing whether vitamin K supplementation can help improve vascular function in people with end-stage renal disease who are undergoing hemodialysis.
Eligible Conditions
- Vitamin K Deficiency
- Cardiovascular Disease
- Renal Disease
- Hemodialysis
- Chronic Kidney Disease
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ change from baseline to 8 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change from baseline to 8 weeks
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Flow-Mediated Dilation (FMD)
Pulse Wave Velocity (PWV)
Secondary study objectives
Prothrombin Time
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: Vitamin K2 (360-mcg/d)Experimental Treatment1 Intervention
The experimental group will take four 90-mcg of vitamin K2 (menaquinone-7; 360-mcg) softgel capsules every day for 8 weeks.
Group II: Placebo-ControlPlacebo Group1 Intervention
The placebo-control group will take four placebo softgel capsules (similar in taste and appearance to the vitamin K2 supplements) every day for 8 weeks.
Find a Location
Who is running the clinical trial?
Augusta UniversityLead Sponsor
215 Previous Clinical Trials
85,630 Total Patients Enrolled
Norman K Pollock, PhDPrincipal InvestigatorAugusta University
1 Previous Clinical Trials
30 Total Patients Enrolled